99mTc-二膦酸盐骨显像中心脏摄取是预后不良的预测因素:来自9616例骨显像的数据
回顾2009至2020年因各种临床指征行骨显像的9616例扫描,0.7%(67例)显示心脏摄取,其中Perugini评分1分47例(70%)、≥2分20例(30%)。随访期间61%(40例)死亡,Perugini评分≥2分者死亡率高于1分者(P=.018)。作者认为心脏摄取提示心脏ATTR淀粉样变虽罕见但易被忽视,且与生存不良相关。
要点
- 9616例骨显像中0.7%(67例)出现心脏摄取,提示心脏ATTR淀粉样变可能。
- 67例中Perugini评分1分47例(70%),≥2分20例(30%)。
- Perugini评分≥2分者死亡率较1分者升高(P=.018)。
核心结论
- 在因不同临床指征行骨显像的患者中,提示心脏ATTR淀粉样变的心脏摄取是罕见但易被忽视的发现,可能妨碍ATTR心肌病的诊断。
- 心脏摄取对生存有不良影响,医生应认识这一罕见但关键的发现,以便及时诊断和治疗。
研究设计与样本
- 回顾性分析2009至2020年因任何临床指征行[99mTc]MDP/DPD骨显像的扫描,按Perugini视觉评分对心脏摄取分层并收集随访数据,共纳入9616例骨显像。
主要发现
- 9616例骨显像中0.7%(n=67)显示心脏摄取。
- 67例中Perugini评分为1分者47例(70%),摄取≥2分者20例(30%),提示心脏ATTR淀粉样变。
- 随访期间(平均47±30个月)40例(61%)死亡。
- 与Perugini评分1分患者相比,Perugini评分≥2分患者死亡率升高(P=.018)。
- 67例中2例接受TTR基因突变检查,结果为阴性。
关键数值与推荐
- 心脏摄取按Perugini视觉评分分层:1分47例(70%),≥2分20例(30%)。
- Perugini评分≥2分者较1分者死亡率升高,P=.018。
临床怎么用
- 作者认为医生应认识骨显像中心脏摄取这一罕见但关键的发现,以便及时诊断和治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone scintigraphy (BS) is highly diagnostic for amyloid transthyretin (ATTR) cardiomyopathy. Prevalence and prognostic value of BS cardiac uptake is not well established. Our aim was to assess the prevalence of subclinical cardiac ATTR amyloidosis in patients undergoing [99mTc]MDP/DPD scintigraphy and to define their phenotype and prognosis. METHODS AND RESULTS: BS scans performed for any clinical indications from 2009 to 2020 were reviewed. Patients were stratified according to Perugini visual score of cardiac uptake. Follow-up data were collected. Among 9616 BS scans, 0.7% (n = 67) showed cardiac uptake. In 47 (70%) patients, Perugini score was 1 and in 20 (30%) patients uptake was ≥ 2, suggesting cardiac ATTR amyloidosis. Forty subjects (61%) died during the follow-up (mean 47 ± 30 months). Compared with patients with Perugini score 1, those Perugini score ≥ 2 showed increased death rate (P = .018). Two (2/67) subjects were investigated for TTR gene mutations resulting negative. CONCLUSIONS: In patients undergoing BS for different clinical indications, cardiac uptake suggesting cardiac ATTR amyloidosis is a rare, but still neglected finding, thus preventing possible diagnosis of ATTR cardiomyopathy. Importantly, cardiac uptake negatively affects the survival. Physicians should be aware of this rare, but crucial finding for timely diagnosis and treatment.
引用
- Salvalaggio A, Cipriani A, Righetto S, et al. Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies. J Nucl Cardiol. 2022. PMID: 35437680. doi:10.1007/s12350-022-02961-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。